ILiAD Biotechnologies, Inc.

About ILiAD Biotechnologies, Inc.

ILiAD Biotechnologies is focused on addressing the global health challenge of pertussis (whooping cough), with a mission to combat the disease that causes 160,000 deaths and 24 million cases annually worldwide.

Products & Services

BPZE1 Vaccine:A live vaccine aimed at preventing pertussis, with a focus on colonization and transmission prevention.

Specialties

Pertussis prevention Vaccine development Live vaccine technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 115000000 MR: - FA: $115 million FAN: 115000000	D: 2026-02-10 FD: 2026-02-10	5 investors

Series B Latest

2026-02-10

$115.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael J. Brennan

SAB Member

R

Ralf Clemens

SAB Member

K

Kathryn M. Edwards

SAB Member

N

Neal Halsey, M.D.

SAB Member

C

Camille Locht

SAB Member

N

Nathalie Mielcarek

SAB Member

View 28 more team members with Pro

Unlock Full Team Directory

Recent News